FDA Advisory Committee Recommends Approval Of Alirocumab Injection For Patients With Hypercholesterolemia

Sunday, June 14, 2015 - 21:50 in Health & Medicine

The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent (alirocumab) Injection for patients with hypercholesterolemia. read more

Read the whole article on

More from

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net